Article Data

  • Views 224
  • Dowloads 117

Original Research

Open Access

A hospital-based rnulticentric study results on gestational trophoblastic disease management status in a developing country

  • S. Sinan Ozalp1,*,
  • 0. T. Yalcin1
  • H. M. Tanir1

1Department of Obstetrics and Gynecology, Gynecologic Oncology Unit, Osmangazi University Faculty of'Medicine, Eski ehir, Turkey

DOI: 10.12892/ejgo200103221 Vol.22,Issue 3,May 2001 pp.221-222

Published: 10 May 2001

*Corresponding Author(s): S. Sinan Ozalp E-mail:

Abstract

Objective: To determine the clinical management of gestational trophoblastic disease in Turkey.

Material and methods: An inquiry form was sent to 55 health centers including university hospitals, maternity hospitals with residency programs and maternity hospitals without residency programs in 1997. The inquiry consisted of questions about the type of classification systems in use, distribution of cases according to those classifications, use of prophylactic chemotherapy and its indications, and drug preference for single-agent or combined chemotherapies.

Results: The overall response rate to the conducted inquiry was 47.1%. A clinical classification system was identified in 60% of the hospitals in Turkey. Generally, methotrexate was the most used single-agent chemotherapy. With regard to first-line combined chemotherapy, MAC (methotrexate, antinomycin-D, cyclophosphamide) was the preferred combination. EMA-CO (etoposide, methotrexate, actinomycin-D, cyclophosphamide, vincristine) was the most common used second-line chemotherapeutic regimen.

Conclusion: Due to insufficient data acquisition from all the medical centers and a lack of national population-based studies, it is difficult to draw a conclusion with respect to the interpretation of the data about the management protocols of gestational trophoblastic disease.

Keywords

Gestational trophoblastic disease; Management; Hospital-based study

Cite and Share

S. Sinan Ozalp,0. T. Yalcin,H. M. Tanir. A hospital-based rnulticentric study results on gestational trophoblastic disease management status in a developing country. European Journal of Gynaecological Oncology. 2001. 22(3);221-222.

References

[1] Semer D. A., Macfee M. S.: "Gestational trophoblastic disease: epidemiology". Seminars in Oncology, 1995, 22 (2), 109.

[2] Hammond C. B., Borchert L. G., Tyreyl L. et al.: "Treatment of metastatic trophoblastic diseases: good and poor prognosis". Am. J. Obstet. Gynecol., 1973, 115, 454.

[3] Berkowitz R. S., Goldstein D. P.: "Gestational trophoblastic disease". In: Berek J. S. (ed.): "Novak's Gynecology". Twelfth edition, Williams and Wilkins, Baltimore 1996, 1261.

[4] Gestational trophoblastic disease: "WHO technical report senes 692". WHO Geneva 1983.

[5] Smith D. B.,N ewslands E. S.,H olden L.,B agshawe K. D.: "Correlation between clinical staging and FIGO staging groups with gestational trophoblastic disease". Br. J. Obstet. Gynaecol., 1993, 100, 157.

[6] Goldstein D. P., Zanten Przybysz I. V., Bernstein M. R., Berkowitz R. S.: "Revised FIGO staging system for gestational trophoblastic tumours; recommendations regarding therapy". J. Reprod. Med., 1998, 43, 37.

[7] Kohorn E. I.: "Assessing and staging of trophoblastic tumors". Trophoblastic Disease Update, 1998, 2, 3.

[8] Hanconck B. W., Welch E. M., Gillespie A. M., Newslands E. S.: "A retrospective comparison of current and proposed staging and scoring systems for persistent gestational trophoblastic disease". Int. J. Gynecol. Cancer, 2000, 10, 318.

[9] Gillespie A. M., Kumar S., Hancock B. W.: "Treatment of persistent trophoblastic disease later than 6 months after diagnosis of molar pregnancy". Br. J. Cancer, 2000, 82 (8), 1393.

[10] Bagshawe K. D., Begent R. H. J., Rustin G. J. S., Brock C., Short D., Holden L. et al.: "EMNCO for high-risk gestational trophoblastic tumors: results from a cohort of 272 patients". J. Clin. Oncol., 1997, 15, 2636.

[11] Hancock B. W., Coleman R. E., Lorigan P. C., Dobson L. S.: "Persistent gestational trophoblastic disease: results of MEA (methotrexate, etoposide,d actinomycin) as first-line chemotherapy in highrisk disease and EA (etoposide and dactinomycin) as second-line therapy for low-risk disease". Br. J. Cancer, 2000, 82 (9), 1547.

[12] Rustin G. J. S., Seckl M. J., Holden L., Mulholland P. J., Newslands E. S.: "Etoposide and cisplatin/etoposide, and actinomycinD (EMA) chemotherapy for patients with high-risk gestational trophoblastic tumors refractory to EMNCO chemotherapy and patients presenting with metastatic placental site trophoblastic tumors". J. Clin. Oncol., 2000, 18, 854.

Abstracted / indexed in

Science Citation Index Expanded (SciSearch) Created as SCI in 1964, Science Citation Index Expanded now indexes over 9,500 of the world’s most impactful journals across 178 scientific disciplines. More than 53 million records and 1.18 billion cited references date back from 1900 to present.

Biological Abstracts Easily discover critical journal coverage of the life sciences with Biological Abstracts, produced by the Web of Science Group, with topics ranging from botany to microbiology to pharmacology. Including BIOSIS indexing and MeSH terms, specialized indexing in Biological Abstracts helps you to discover more accurate, context-sensitive results.

Google Scholar Google Scholar is a freely accessible web search engine that indexes the full text or metadata of scholarly literature across an array of publishing formats and disciplines.

JournalSeek Genamics JournalSeek is the largest completely categorized database of freely available journal information available on the internet. The database presently contains 39226 titles. Journal information includes the description (aims and scope), journal abbreviation, journal homepage link, subject category and ISSN.

Current Contents - Clinical Medicine Current Contents - Clinical Medicine provides easy access to complete tables of contents, abstracts, bibliographic information and all other significant items in recently published issues from over 1,000 leading journals in clinical medicine.

BIOSIS Previews BIOSIS Previews is an English-language, bibliographic database service, with abstracts and citation indexing. It is part of Clarivate Analytics Web of Science suite. BIOSIS Previews indexes data from 1926 to the present.

Journal Citation Reports/Science Edition Journal Citation Reports/Science Edition aims to evaluate a journal’s value from multiple perspectives including the journal impact factor, descriptive data about a journal’s open access content as well as contributing authors, and provide readers a transparent and publisher-neutral data & statistics information about the journal.

Submission Turnaround Time

Conferences

Top